Expanding Non-Injectable Insulin Market Fueled by Escalating Obesity and Diabetes Epidemics Is Supporting Development Across The Non-injectable Insulin Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Non-injectable Insulin Market Change Between 2026 And 2030?

The non-injectable insulin market has experienced significant growth in recent years. It is forecast to increase from $2.14 billion in 2025 to $2.35 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.9%. The market’s expansion in the historical period is due to factors such as the increasing prevalence of diabetes, a rising patient preference for non-injective therapies, advancements in insulin formulation, government initiatives promoting diabetes care, and growing awareness about diabetes complications.

The non-injectable insulin market is projected to experience significant expansion in the upcoming years. It is foreseen to reach $3.41 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period is attributable to technological advancements in oral and inhalable insulin, the integration of digital health solutions, an expanding geriatric population, the development of healthcare infrastructure in emerging markets, and personalized medicine approaches for diabetes treatment. Prominent trends for this period include oral insulin delivery systems, pulmonary insulin inhalers, patient-centric diabetes management, non-invasive monitoring and dosing, and formulation innovations aimed at improving bioavailability.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

Which Drivers Are Advancing The Non-injectable Insulin Market Growth?

The escalating prevalence of obesity and diabetes is anticipated to fuel the expansion of the non-injectable insulin market. Obesity involves an excessive accumulation of body fat, typically resulting from an imbalance between caloric intake and expenditure, while diabetes mellitus constitutes a group of metabolic disorders marked by persistently high blood sugar levels. Non-injectable insulin offers a treatment alternative for both diabetes and obesity, potentially enhancing management by overcoming obstacles to traditional insulin therapy, providing benefits for weight management, and offering more convenient treatment options. For example, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people globally were living with diabetes, a figure projected to more than double to 1.3 billion people by 2050. Consequently, the increasing burden of obesity and diabetes is a significant driver for the growth of the non-injectable insulin market.

How Are Different Segment Groups Identified Within The Non-injectable Insulin Market?

The non-injectable insulin market covered in this report is segmented –

1) By Insulin Type: Oral Insulin, Inhaled Insulin, Nasal Insulin, Buccal Or Sublingual Insulin, Transdermal Insulin

2) By Product: Pills, Sprays, Other Products

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Oral Insulin: Oral Insulin Tablets, Oral Insulin Capsules, Enteric-Coated Oral Insulin, Nanoparticle-Based Oral Insulin

2) By Inhaled Insulin: Dry Powder Inhaled Insulin, Aerosolized Insulin, Pulmonary Insulin Delivery Systems

3) By Nasal Insulin: Nasal Spray Insulin, Nasal Gel Insulin, Nasal Powder Insulin

4) By Buccal Or Sublingual Insulin: Buccal Spray Insulin, Sublingual Insulin Films, Oral Mucosal Insulin Drops

5) By Transdermal Insulin: Insulin Patches, Microneedle-Free Transdermal Systems, Iontophoresis-Based Insulin Delivery

Which Trends Are Supporting The Evolution Of The Non-injectable Insulin Market?

Leading companies within the non-injectable insulin market are prioritizing breakthroughs in drug delivery systems, including needle-free oral insulin sprays, aiming to enhance the quality of life for individuals managing their diabetes through frequent insulin injections. This type of spray offers a pain-free, needle-free method for blood glucose regulation, providing a convenient choice since doses are administered orally. As an illustration, NiedlFree Technologies, an India-based technology platform, launched Ozulin, an oral insulin spray, in November 2023. The design of this oral insulin spray aims to present a more accessible solution for people with diabetes, particularly for those who encounter difficulties with conventional injectable insulin techniques. Should it receive approval, Ozulin could significantly alter diabetes treatment, presenting a more convenient and painless substitute for insulin injections.

Which Key Players Are Active In The Non-injectable Insulin Market?

Major companies operating in the non-injectable insulin market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca, Takeda Pharmaceutical, Abbott Laboratories, MannKind Corporation, Biocon Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Wockhardt Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd.

Access The Complete Non-injectable Insulin Market Report:

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Which Region Accounts For The Highest Share Of The Non-injectable Insulin Market?

North America was the largest region in the non-injectable insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Non-injectable Insulin Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

Browse Through More Reports Similar to the Global Non-injectable Insulin Market 2026, By The Business Research Company

Non Injectable Insulin Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Insuman Market Report 2026

https://www.thebusinessresearchcompany.com/report/insuman-global-market-report

Oem Insulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/oem-insulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795